tradmap

CHRS Coherus Oncology, Inc.

$1.36 -3.55%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Coherus Oncology, Inc. (CHRS) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $210 million. Shares last traded at $1.36, 47.9% below their 52-week high. Over the past year the stock is up 8.4%. Net profit margin is -259.4%, below the peer median of 5.3%. Revenue grew 59.8% year over year.

Market Cap
$210M
Shares Out
154.5M
EPS (TTM)
$3.17
P/E Ratio
0.43
P/S Ratio
4.13
P/B Ratio
3.45
Dividend / Share
Dividend Yield
52-Week High
$2.61
52-Week Low
$1.09
Volume
40,384
Avg Vol (3m)
60,316.317

Performance

1W
-7.48%
1M
-2.16%
3M
-13.38%
6M
-22.73%
YTD
-0.73%
1Y
+8.37%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
49.55
SMA (50)
$1.40
SMA (200)
$1.57
Price vs SMA50
-3.04%
Price vs SMA200
-13.43%
ATR (14)
$0.09

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$51M
Net Income
$-132M
Gross Margin
68.9%
Operating Margin
-311.6%
Net Margin
-259.4%
Return on Equity
-217.2%
Return on Assets
-69.1%
Current Ratio
1.77
Debt / Equity
1.21
Revenue Growth (YoY)
+59.8%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-0.40 2026-08-05
Q1 2026 $-0.28 2026-05-11
FY 2025 $1.43 2026-03-09
Q3 2025 $1.77 2025-11-06
Q2 2026 $2.08 2026-08-05
Q2 2026 $2.57 2026-08-05

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

CHRS vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
4.13 / 19.49 med
-79% discount
Net margin vs peers
-259.4% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.